Chan–Navarro CA, Jiménez–Ríos MA, Solares–Sánchez ME, Trujillo C

Language: Spanish
References: 12
Page: 115-120
PDF size: 119.45 Kb.

ABSTRACT

Every year, nearly 700,000 men are diagnosed with prostate cancer worldwide and more than 200,000 of them die from this disease. Hormone deprivation therapies are effective in slowing down disease progression, but they also provoke adverse side effects in bone and skeletal health in prostate cancer patients by reducing bone mineral density and normal bone turnover rate. Cancer itself causes bone-related complications because bone metabolism is affected by osteoclast and osteoblast imbalance and impairment. Complications arising from both the disease and treatment significantly affect patient quality of life in the form of pathologic fractures, disability, severe pain and the high cost of treatment. Given the necessity of the anti-androgen approach used in prostate cancer treatment, these bone complications were routinely accepted by clinicians in the past as inevitable side effects of prostate cancer management and were treated only palliatively. Today, however, potent bisphosphonates, developed only a few years ago, are the first-line therapy for managing these complications in cancer patients. They are especially useful in prostate cancer treatment because these patients commonly present with bone mineral density loss and metastatic complications. This article aims to provide clinicians with an insight into the role that zoledronic acid (the most potent bisphosphonate to date) plays in the current overall therapeutic approach to prostate cancer practiced worldwide.

REFERENCES

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase No. 5, version 2.0, IARC Press, Lyon. 2004.

2. Morote J, Martinez E, Trilla E, et al. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment. Eur Urol. 2003;44 (6):661-5.

3. Wei JT, Gross M, Jaffe CA, et al. Androgen deprivation therapy (ADT) for prostate cancer results in significant loss of bone density. Urology. 1999; 54 (4):607-11.

4. Hussain SA, Weston R, Stephenson RN, George E, Parr NJ. Immediate dual energy x-ray absorptiometry reveals a high incidence of osteoporosis in patients with advanced prostate cancer before hormonal manipulation. BJU Int. 2003; 92(7):690-4.

5. Matthew RS, Won Chan Lee, et al. Gonadotropin-releasing hormone agonist and fracture risk: a claimbased cohort study of men with non-metastatic prostate cancer. JCO, 2005: Vol. 31, No. 31.

6. Greenspan SL, Coates P, Sereika SM, et al. Bone loss after initiation of androgen therapy in patients with prostate cancer. J Clin Endocrinol Metab. 2005; 90 (12):6410-6417.

7. Guise TA, Eastha JA. Cancer treatment induced bone loss in prostate cancer: pathophysiology, preclinical findings and treatment with zoledronic acid. Eur Urol Suppl 3 (2004) 46-54.

8. Smith MR. Therapy insight: osteoporosis during hormone therapy for prostate cancer. Nat Clin Pract Urol. 2005; 2(12):608-15.

9. Grupo Medicina Basada en Evidencias de Galicia, España. Osteoporosis. Guías Clínicas 2003; 3(24).

10. Shanhinian VB, Kuo YF et al. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005; 13:352(2):154-64.

11. Khan MA, Partin AW. Bisphosphonates in metastatic prostate cancer. Rev Urol. 2003 Summer;5(3):204-6.

12. Smith MR, Eastham J, Gleason DM. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J Urol. 2003; 169(6):2008-12.